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http://dx.doi.org/10.1016/j.jaad.2014.06.034Fig 1. Scleromyxedema. Skin-colored subcutaneous nod-
ules on the forehead and eyelid edema.
Fig 2. Scleromyxedema. Photomicrograph of skin biopsy
specimen, showing pronounced deposit ofmucin associated
with increase in fibroblasts and collagen. (Hematoxylin-
eosin stain; original magnification:340.)Atypical scleromyxedema with prominent
nodular lesions associated with immune
thrombocytopenia: An unusual presentation
To the Editor: Scleromyxedema (SM) is a rare
cutaneous mucinosis that usually occurs with mono-
clonal gammopathy ([83.2%), predominantly an
IgG lambda subtype.1,2 SM may show a great variety
of extracutaneous manifestations ( gastrointestinal,
musculoskeletal, neurologic, pulmonary, cardiac,
and renal involvement) leading to significant
morbidity and mortality.1,2 We report a case of SM
with prominent scalp involvement, presence of
nodular lesions, and immune thrombocytopenia.
A 69-year-old woman presented with a 2-week
history of facial edema and progressive eruption.
The patient also reported severe scalp pruritus and
increased hair loss.
On physical examination, skin-colored firm pap-
ules, nodules, and edema of the face and both hands
were observed. The papules were initially located on
the scalp, neck, and back of the auricular area, then
gradually involved upper aspect of the trunk and the
surrounding skin showed scleroderma-like indura-
tion in these areas. Several nodules, 4 to 10 mm in
size, were present on the scalp, forehead (Fig 1), and
side portions of the chin.
Pathological examination of biopsy specimens
from a nodular scalp lesion and of a neck papule
(Fig 2) revealed an increase in fibroblasts, collagen,
and deposits of mucin in the papillary and mid-
reticular dermis. Laboratory analysis showed a pro-
gressive low platelet count (60-10 103/L, normal
range 150-400 103/L, platelet count within normal
limits 6 months earlier), with a normal peripheral
blood smear result and a normocellular bone
marrow with trilineage hematopoiesis. Serum pro-
tein electrophoresis, immunofixation electropho-
resis of serum and urine, and immunoglobulin free
light chain assays did not show paraproteinemia.
Other laboratory examination findings including
thyroid function were within normal limits and
autoantibody screening produced negative results.
Computed tomographic scans of the chest,
abdomen, and pelvis showed no relevant abnormal-
ities. Electromyography detected signs consistentOpen access under CC BY-NC-ND license.with a right carpal tunnel syndrome and peripheral
sensory and motor neuropathy. Based on clinical
manifestations, and histopathological and laboratory
data, the diagnosis of SM with a secondary immune
thrombocytopenia was made. The patient was
treated with 3 methylprednisolone pulses of 1 g,
followed by 1 mg/kg/d of prednisone for 1 month,
and intravenous immunoglobulins (2 g/kg per
cycle). Administration of a second course of intrave-
nous immunoglobulins, delivered after 4 weeks,
dramatically improved skin manifestations; however
persistence of low platelet count prompted the
addition of romiplostim, a thrombopoietin-receptor
agonist. The prescribed corticosteroids were gradu-
ally tapered off and romiplostim was withdrawn.
After 12 months of follow-up, she remains asymp-
tomatic and platelet count was within normal limits
J AM ACAD DERMATOL
VOLUME 71, NUMBER 4
Letters e159with a maintenance therapy of intravenous immu-
noglobulins every 2 months.
The characteristic cutaneous manifestations in
SM, also known as generalized lichen myxedema-
tosus,1 is a widespread eruption of 2- to 3-mm, firm,
waxy papules, often in linear arrays, and the
sclerodermoid induration of the skin. These char-
acteristic skin findings were observed concomi-
tantly with other unusual clinical findings in this
patient. Nodular eruption3,4 and scalp involvement
leading to alopecia have been reported only
sporadically.3 Interestingly, the recently reported
cases, with a prominent nodular eruption, pre-
sented in absence of underlying paraproteinemia.3,4
Associated hematologic diseases in SM include
Waldenstr€om macroglobulinemia, Hodgkin lym-
phoma, and non-Hodgkin lymphoma, particularly
after chemotherapy with melphalan.1 To our
knowledge, immune thrombocytopenia has not
been reported previously in SM. Based on the
current classification,1 a final diagnosis of atypical
form was made (SM without monoclonal gammop-
athy). Long-term follow-up to further characterize
the natural course and prognosis in these patients is
required.
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To the Editor: Vemurafenib (PLX4032, Zelboraf,
Roche Registration Ltd, Welwyn Garden City, UK)
is a selective inhibitor of the oncogenic BRAF kinase
activity.1 The BRAFV600 mutation is the most com-
mon protein kinase mutation reported in melanoma
with a frequency of 40% to 50%.2,3 BRAF is a member
of the RAF kinase family, which acts in the ERK/MAP
kinase pathway, a signaling cascade regulating
cellular proliferation, differentiation, and survival.3
Vemurafenib treatment of patients with metastatic
melanoma carrying the BRAFV600E mutation results
in partial or complete tumor regression in the
majority of patients and increases overall survival
time.4,5
Common adverse events during vemurafenib
therapy include photosensitivity, fatigue, rash, and
arthralgia.4,5 Furthermore, approximately one third
of the patients develop epithelial tumors of the skin
such as warts, squamous cell carcinomas, and
keratoacanthomas.1,4,5
Hereby, we wish to report a case of lupus
erythematosuselike skin eruption after vemurafenib
therapy in a 70-year-old woman with stage IIIc
progressive metastatic melanoma (pT4bN3M0).
After excision of a 8-mm thick primary tumor on
the left upper aspect of her back and lymph node
dissection of the left axilla (7 metastatic of 19 lymph
nodes), the tumor reoccurred within 26 months.
Because the melanoma cells were found to have the
BRAFV600E mutation, vemurafenib therapy was
started at the regular daily dosage of 1920 mg. The
treatment was well tolerated for a total of 4 months
but then needed to be paused for 4 months because
of fatigue and nausea. Vemurafenib was reinitiated at
a total dose of 960 mg daily for 2 months and then
increased to 1920 mg twice daily for another 2
months. Because of gastrointestinal discomfort and
flareup of a rash the treatment was aborted. The rash
started with erythematous macules on the face and
subsequently over the next 2 to 4 weeks progressed
into demarcated, infiltrated, scaly plaques that were
symmetrically distributed over all sun-exposed body
areas, particularly the face, decollete, and upper
aspect of the back (Fig 1, A). Histopathology
revealed interface dermatitis with follicular plugging
and dermal mucin deposition consistent with a lupus
